PR93102

SEATTLE, Nov. 17, 2021 /PRNewswire=KYODO JBN/ --

-- Organization saw growth in AD Workbench users, data partners, and patient

datasets from across the globe, including from low- and middle-income

countries  

Today, the Alzheimer's Disease Data Initiative (ADDI) marked one year of

transforming how Alzheimer's disease and related dementias will be treated by

significantly increasing access to data from academic institutions,

government-sponsored organizations, pharmaceutical companies, and others

dedicated to data sharing and collaboration.

Logo - https://mma.prnewswire.com/media/1335810/ADDI_Logo.jpg

"One year ago, ADDI took our first steps on the path to tackling the hard

problems of data access in Alzheimer's research in close collaboration with

partners who share our vision," said Executive Director Tetsuyuki Maruyama. "We

started by dedicating the resources needed to build a platform that breaks down

barriers so that the research community can access, analyze, store and share

the data needed to accelerate progress on treating and curing Alzheimer's

disease. The progress ADDI and our partners have made in such a short amount of

time is inspiring."

Since its launch last year, ADDI's cloud-based Alzheimer's Disease (AD)

Workbench has built a community of over 2,000 users in 80 countries, who have

created more than 200 workspaces with access to over 35 datasets, many of which

include data from diverse populations around the world. Researchers can also

bring their own data into a secure workspace to analyze and make connections

across multiple datasets. The trove of data available on the AD Workbench at no

cost to registered users includes observational clinical trials, synthetic

cohort studies, and synthetic brain images, all accessible in a secure and

centralized location that allows researchers to explore freely field-level

metadata and investigate datasets.

In addition to these milestones, ADDI also celebrated the following

achievements:

    - The first European data partner, the European Prevention of Alzheimer's

      Dementia (EPAD) Consortium, which includes their first academic partner

      – the University of Edinburgh.

    - The first major industry partnership with Eli Lilly and Company (Lilly),

      which shared their GERAS-EU study dataset. This was later followed by

      three other GERAS studies that now include data from seven countries

      (France, Germany, Italy, Japan, Spain, the United Kingdom, and the

      United States).

    - Access to 19 new datasets from Lilly and GlaxoSmithKline (GSK) through

      a partnership with Vivli and interoperability with the Vivli platform.

    - The first data sharing partner in Asia, the Indian Institute of Science

      Centre for Brain Research, which will provide federated access through

      the AD Workbench to home visit data.

"The success of our Data Science Challenge substantially increased user

engagement on our platform and the introduction of data sharing capability in a

federated manner effectively addressed data contributors' requirement to be

able to share data securely and remotely," said Mukta Phatak, Director of Data

Science at ADDI. "The AD Workbench will continue to expand and evolve with the

addition of new datasets, analysis tools, and other products and services to

meet the needs of the research community who are working to find treatments and

cures for this disease."

ADDI is currently in the process of adding more than 15 additional datasets in

the next year. They also plan to expand their data sharing community into a

gateway where researchers, data providers, and the broader Alzheimer's and

related dementia community can come together to share ideas, post questions,

and offer tools or resources that further efforts to find answers to shared

challenges.

For more information please visit: www.Alzheimersdata.org

Alzheimer's Disease Data Initiative (ADDI), a 501 (c)(3) medical research

organization (MRO) in partnership with the University of Washington, is

dedicated to advancing scientific breakthroughs in the treatment of Alzheimer's

disease and related dementias. ADDI aims to increase interoperability of

existing data platforms globally, increase sharing of dementia-related data

from academic and industry sources, and empower scientists to find, search,

combine, and analyze data that could lead to new discoveries in dementia

research. ADDI also aims to enhance or fill gaps in datasets, including

enabling the generation of more demographically representative datasets.

LinkedIn: AlzheimersData (

https://c212.net/c/link/?t=0&l=en&o=3359495-1&h=2035512282&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Falzheimersdata%2F&a=AlzheimersData

) Twitter: AlzData (

https://c212.net/c/link/?t=0&l=en&o=3359495-1&h=386413442&u=https%3A%2F%2Ftwitter.com%2FAlzData&a=AlzData

)

SOURCE: Alzheimer’s Disease Data Initiative (ADDI)

CONTACT: Eric Conrad, +1 (202) 813-4815 | eric.conrad@gmmb.com